Tuesday, 26. March 2019

IDT Biologika Receives Six 2019 CMO Leadership Awards

DESSAU, Germany & ROCKVILLE, Md – IDT Biologika, a globally integrated contract manufacturer of vaccines and biopharmaceuticals, honored with six 2019 CMO Leadership Awards in all categories, including Capabilities, Compatibility, Expertise, Quality, Reliability and Service. Sponsored by Life Science Leader magazine, the annual awards recognize the top contract manufacturing organizations (CMOs) serving the pharmaceutical and biopharmaceutical industries.

IDT Biologika Chief Executive Officer Dr. Jürgen Betzing accepted the 2019 CMO Leadership Awards on behalf of the company. „With our wide range of innovative technologies, experience and competence in biopharmaceutical development and production, we advance our clients’ biopharmaceutical products to prevent and treat diseases that impact the health of people worldwide. IDT is a valued partner for all organizations working to bring new vaccines and biopharmaceutical products to patients,“ said Dr. Betzing. „The success of our customers is highlighted by honors in each of the six categories of the CMO award in which we are decorated this year. We are a true partner, offering our customers seamless end-to-end solutions to meet all of their vaccines and biologics needs. Together, we can combat diseases and epidemics worldwide.“

Winners were evaluated based on real-world experiential data and feedback from decision makers who work with contract manufacturing suppliers. IDT was judged by its customers as a top performer among more than 120 CMOs. The company achieved this high honor in six of six categories across 23 performance metrics considered important to the selection of a CMO and based on customers’ direct experience working with IDT on an outsourced project within the last 18 months. Life Science Leader teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers.

The award adds to IDT’s distinguished reputation in the contract services business and celebrates the company’s ongoing commitment to manufacturing excellence. Today, IDT offers a wide range of services during all phases of vaccine and biopharmaceutical development – from early research and process development through clinical and commercial manufacturing.

News Overview

IDT Biologika to concentrate on human vaccines and pharmaceuticals more info

Ceva Santé Animale and IDT Biologika GmbH more info

IDT Biologika Awarded 10-Year NIH Contract more info

CEPI Awards Contract Worth Up To USD$36 million to Consortium led by IDT to Develop MERS Vaccine more info

25th anniversary of the privatization of IDT Biologika more info

IDT Biologika acquires Dr. Felgenträger, located in the BioPharmaPark Dessau more info

CMO Leadership Award 2018 more info

A second managing director for IDT Biologika more info

Official transfer of ownership more info

Plans to Build Out New, State-of-the-Art Vaccine Manufacturing Hub in Ontario more info